Rexahn Pharmaceuticals (RNN) says it intends to offer shares of its common stock and warrants in an underwritten public offering. The shares are being offered as units, with no amount given at present. Earlier today the company announced it would be receiving additional funding from Teva Pharmaceutical (TEVA) for the development of its potential tumor treatment RX-3117. Burrill and Maxim Group are acting as joint book-running mangers for the offering.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs